Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lavipharm financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€0.8
2024-10-29
Market Capitalization
€129.7 M
2024-10-29
Revenue
€56.4 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 34.1M | 33.6M | 37.6M | 39.7M | 46.0M | 57.6M | 56.4M |
| Cost of goods sold | 15.9M | 17.2M | 21.0M | 23.4M | 27.6M | 31.0M | 26.7M |
| Gross profit | 20.2M | 20.2M | 17.3M | 17.2M | 20.2M | 27.4M | 32.3M |
| Gross profit margin, % | 59.4% | 60.1% | 46.0% | 43.4% | 43.9% | 47.5% | 57.2% |
| Operating expense total | 15.4M | 13.9M | 13.2M | 14.5M | 15.9M | 19.4M | 21.8M |
| Depreciation and amortization | 1.4M | 1.4M | 1.6M | 1.5M | 1.9M | 4.3M | 4.7M |
| EBITDA | 4.8M | 6.3M | 4.1M | 2.8M | 4.3M | 8.0M | 10.5M |
| EBITDA margin, % | 14.1% | 18.8% | 10.9% | 6.9% | 9.3% | 13.9% | 18.6% |
| EBIT | 4.8M | 4.9M | 5.3M | 5.6M | 3.6M | 4.8M | 5.7M |
| EBIT margin, % | 14.0% | 14.5% | 14.0% | 14.2% | 7.9% | 8.3% | 10.2% |
| Interest income | 29.0K | 21.0K | 26.0K | 21.0K | 30.0K | 270.0K | 146.0K |
| Interest expense | 1.9M | 1.9M | 1.9M | 1.8M | 1.7M | 2.3M | 2.1M |
| Pre tax profit | 2.9M | 2.1M | 3.4M | 2.7M | 2.1M | 3.1M | 3.9M |
| Income tax expense | 1.6M | (3.2M) | 1.2M | 1.0M | 1.3M | 1.3M | (5.1M) |
| Net Income | 1.3M | 5.3M | 2.2M | 1.7M | 830.0K | 1.9M | 9.0M |